About Fluorogenics
Fluorogenics is a Healthcare company based in Salisbury (United Kingdom) founded in 2011, and was acquired by New England Biolabs in May 2021. It operates as a lyophilized reagents for stable nucleic acid amplification are supplied. The company has 8 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Genomics. Its legal entity is NEW ENGLAND BIOLABS LYOPHILIZATION SCIENCES LTD. Its competitors include ArcherDX, Qiagen, Devyser, Third Wave Technologies and DxTerity and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Fluorogenics was founded in 2011 and is based in Salisbury, United Kingdom. Operations focus on molecular biology products, particularly ambient-stored nucleic acid amplification reagents stabilized through lyophilization for up to three years at 15-30C. The portfolio encompasses master mixes, kit reagents, vial products for 96- and 384-well plates, cirrus strips, and taqtonix, supporting PCR applications in research and diagnostics.
- Headquarters Salisbury, United Kingdom
- Employees 8
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website fluorogenics.co.uk
- Social LinkedIn X Facebook
- Acquired by New England Biolabs (May 2021)
- Legal Name New England Biolabs Lyophilization Sciences Ltd.
- Date of Incorporation 26 Aug, 2011
- Jurisdiction HITCHIN, ENGLAND
- Latest Funding Round$56.11K (USD), Grant
Sep 2016
- InvestorsEuropean Union
& 2 more
- Employee Count8
- Acquired byNew England Biolabs
(May 2021)
Funding Insights of Fluorogenics
- Total Rounds 2
- Last Round Grant — $56,109
- Investors Count 2
All 2 funding rounds of Fluorogenics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2016 | $56,109 | Grant | – | – | |
| Jun 2016 | – | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Fluorogenics
Fluorogenics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, New England Biolabs and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Molecular biology reagents company | 1970 | neb.com | Ipswich, United Kingdom |
Investor details for Fluorogenics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Fluorogenics
4 dated milestones of Fluorogenics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Fluorogenics is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $56K.
- Exit Acquired by New England Biolabs.
Competitors of Fluorogenics
Fluorogenics has 10 listed competitors in our database, 8 of them funded. They include ArcherDX, Qiagen, Devyser, Third Wave Technologies and DxTerity, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| qiagen.com | 1984 | Hilden, Germany | – | 104 | Products and reagents for molecular diagnostic assays are supplied. | |
| devyser.com | 2004 | Stockholm, Sweden | $15.48M | – | Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders | |
| twt.com | 1993 | Xiamen, China | $19.3M | – | Molecular diagnostic devices and reagents are developed and marketed. | |
| dxterity.com | 2006 | Los Angeles, United States | $3.75M | – | Provider of a direct-to-consumer, non-clinical genetic tests | |
| dhiusa.com | 1983 | Athens, United States | $10M | 1,103 | Molecular diagnostic kits for infectious diseases are developed and manufactured. | |
| predictimmune.com | 2017 | Cambridge, United Kingdom | $18.32M | 15 | Tools for diagnosing immune-mediated inflammatory diseases are developed. | |
| gen-probe.com | 1996 | San Diego, United States | – | – | Provides clinical diagnostics, blood screening, and research products. | |
| kiomedpharma.com | 2012 | Herstal, Belgium | $6.73M | 20 | Bio-polymer chitosan products are developed for medical uses. | |
| thunder-bio.com | 2018 | Jiaxing, China | $15.47M | – | Microfluidic technology is developed for diagnostic and research applications. |
Detailed competitors of Fluorogenics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Fluorogenics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fluorogenics
Complete news archive for Fluorogenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fluorogenics
Fluorogenics was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Fluorogenics is headquartered in Salisbury, United Kingdom. It is registered at Salisbury, Wiltshire, United Kingdom.
Fluorogenics has 8 employees.
Fluorogenics was founded in 2011 and is based in Salisbury, United Kingdom. Operations focus on molecular biology products, particularly ambient-stored nucleic acid amplification reagents stabilized through lyophilization for up to three years at 15-30C. The portfolio encompasses master mixes, kit reagents, vial products for 96- and 384-well plates, cirrus strips, and taqtonix, supporting PCR applications in research and diagnostics.
Fluorogenics has 3 investors. Key investors include European Union, New England Biolabs, and EIC Fund.
Fluorogenics operates through New England Biolabs Lyophilization Sciences Ltd..
Yes. Fluorogenics was acquired by New England Biolabs in May 2021.